A biotechnological company which mission is to generate robust clinical therapeutic and diagnostic candidates available for development and commercialization partnerships with pharmaceutical companies.
Digna develops new drugs from CIMA, a leading private biomedical research centre, focused on four clinical areas: oncology, cardiovascular physiopathology, neuroscience, and gene therapy and hepatology.
DIGNA biotech has 18 products including 12 therapeutic candidates, 4 clinical-Stage Products, panning 23 indications across 6 key franchises, as well as 4 diagnostic tests, and 2 research products.
DIGNA leverages world-class scientific and clinical expertise to push medical innovations through early clinical development, reduce financial risk, and thereby increase their partnering appeal to suitable drug and diagnostic developers.
Topical formulation of peptide 144 transforming growth factor (TGF) beta 1 inhibitor
Digna Biotech regains all rights to Disitertide (P144) to treat skin conditions
Would you like to receive updates about Digna Biotech? Sign up for our newsletter.